



GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates

SUPPLEMENTARY MATERIALS


SUPPLEMENTARY FIGURES AND TABLES




Supplementary Figure 1: ¹H-NMR of compound 1b.




Supplementary Figure 2: ¹³C-NMR of compound 1b.




Supplementary Figure 3: ¹H-NMR of compound 2b.




Supplementary Figure 4: ¹³C-NMR of compound 2b.




Supplementary Figure 5: ¹H-NMR of compound 3b.




Supplementary Figure 6: ¹³C-NMR of compound 3b.




Supplementary Figure 7: ¹H-NMR of compound 4b.


Supplementary Figure 8: ^{13}C -NMR of compound 4b.




Supplementary Figure 9: ¹H-NMR of compound 1c.




Supplementary Figure 10: ¹³C-NMR of compound 1c.




Supplementary Figure 11: ¹H-NMR of compound 2c.




Supplementary Figure 12: ¹³C-NMR of compound 2c.




Supplementary Figure 13: ¹H-NMR of compound 3c.




Supplementary Figure 14: ¹³C-NMR of compound 3c.



Supplementary Figure 15: ¹H-NMR of compound 4c.




Supplementary Figure 16: ¹³C-NMR of compound 4c.




No.	RT (min)	Concentration(%)	Area	Height
1	4.091	2.91	45455	1522
2	5.771	97.09	1516636	161993


Supplementary Figure 17: Purity confirmation of 5a by HPLC.




Supplementary Figure 18: Mass spectrum of compound 5a.



Supplementary Figure 19: ¹H-NMR of compound 5b.




Supplementary Figure 20: ¹³C-NMR of compound 5b.




No.	RT (min)	Concentration(%)	Area	Height
1	3.878	1.547	29820	1530
2	5.351	98.46	1897343	203958


Supplementary Figure 21: Purity confirmation of 5b by HPLC.




Supplementary Figure 22: Mass spectrum of compound 5b.




Supplementary Figure 23: IR spectrum of compound 5b.



Supplementary Figure 24: ¹H-NMR of compound 5c.




Supplementary Figure 25: ^{13}C -NMR of compound 5c.




No.	RT (min)	Concentration(%)	Area	Height
1	2.248	1.594	16525	3292
2	4.053	1.439	14922	1012
3	5.305	96.96	1005108	114608


Supplementary Figure 26: Purity confirmation of 5c by HPLC.




Supplementary Figure 27: Mass spectrum of compound 5c.



Supplementary Figure 28: IR spectrum of compound 5c.



Supplementary Figure 29: Cytotoxicity assays (MTS assays). concentration response curves of six cancer cell lines (HT29, H460, DU145, A549, SKOV3, MCF-7) treated with sugar conjugated platinum complexes 5a, 5b, 5c and oxaliplatin.



Supplementary Figure 30: Cytotoxicity assays on EBAS-2B-CM. survival rates of normal epithelial cells after 72 h treatment with sugar conjugated platinum complexes 5a and oxaliplatin (6.25 μ M each) (* $p < 0.05$ compared to oxaliplatin group).